Short Interest in Aptorum Group Limited (NASDAQ:APM) Drops By 26.8%

Aptorum Group Limited (NASDAQ:APM) saw a large drop in short interest in September. As of September 15th, there was short interest totaling 227,700 shares, a drop of 26.8% from the August 31st total of 311,200 shares. Currently, 5.3% of the company’s stock are short sold. Based on an average daily volume of 9,700,000 shares, the short-interest ratio is presently 0.0 days. Based on an average daily volume of 9,700,000 shares, the short-interest ratio is presently 0.0 days. Currently, 5.3% of the company’s stock are short sold.

Wall Street Analyst Weigh In

A number of equities analysts have recently commented on APM shares. Wall Street Zen raised Aptorum Group to a “sell” rating in a research report on Saturday, September 20th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Aptorum Group in a research note on Saturday, September 27th. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the company currently has an average rating of “Sell”.

Aptorum Group Price Performance

Shares of NASDAQ APM opened at $2.32 on Tuesday. The stock’s 50-day simple moving average is $1.83 and its 200-day simple moving average is $1.30. Aptorum Group has a fifty-two week low of $0.46 and a fifty-two week high of $7.49.

About Aptorum Group

Aptorum Group Limited, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic products for the treatment of infectious diseases and cancer. The company operates in the Therapeutics and Non-Therapeutics segments. Its pipeline products include SACT- 1 for neuroblastoma and other cancer types; SACT-COV19 for the treatment of coronavirus disease; ALS-4 to treat bacterial infections caused by staphylococcus aureus, including MRSA; and ALS-1 to treat viral infections caused by influenza virus A.